UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 61

Sortiert nach

Cancer progression mediated by horizontal gene transfer in an in vivo model

PloS one, 2012-12, Vol.7 (12), p.e52754

2012

Volltextzugriff (PDF)

Orlistat as a FASN inhibitor and multitargeted agent for cancer therapy

Expert opinion on investigational drugs, 2018-05, Vol.27 (5), p.475-489

2018

Volltextzugriff (PDF)

A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes

BMC cancer, 2005-04, Vol.5 (1), p.44-44, Article 44

2005

Volltextzugriff (PDF)

Ether à go-go potassium channels as human cervical cancer markers

Cancer research (Chicago, Ill.), 2004-10, Vol.64 (19), p.6996-7001

2004

Volltextzugriff (PDF)

Familial erythrocytosis 2 and von Hippel-Lindau disease in the same pediatric patient

Boletín médico del Hospital Infantil de México, 2021-07, Vol.78 (4), p.341-345

2021

Volltextzugriff (PDF)

NAT2 global landscape: Genetic diversity and acetylation statuses from a systematic review

PloS one, 2023-04, Vol.18 (4)

2023

Volltextzugriff (PDF)

NAT2 global landscape: Genetic diversity and acetylation statuses from a systematic review

PloS one, 2023-04, Vol.18 (4), p.e0283726-e0283726

2023

Volltextzugriff (PDF)

Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines

Cancer cell international, 2006-01, Vol.6 (1), p.2-2, Article 2

2006

Volltextzugriff (PDF)

Analysis of the CAG tract length in the Androgen Receptor gene in Mexican patients with nonsyndromic cryptorchidism

Journal of pediatric endocrinology & metabolism : JPEM, 2021-07, Vol.34 (7), p.843

2021

Volltextzugriff (PDF)

ctDNA Is Useful to Detect Mutations at Codon 641 of Exon 16 of EZH2, a Biomarker for Relapse in Patients with Diffuse Large B-Cell Lymphoma

Cancers, 2022-09, Vol.14 (19), p.4650

2022

Volltextzugriff (PDF)

Growth inhibition and transcriptional effects of ribavirin in lymphoma

Oncology reports, 2019-09, Vol.42 (3), p.1248-1256

2019

Volltextzugriff (PDF)

A Cohort Study of the Prognostic Impact of Exon-16 EZH2 Mutations in a Mexican-Mestizo Population of Patients with Diffuse Large B-Cell Lymphoma

Revista de investigacion clinica, 2021-11, Vol.73 (6), p.362-370

2021

Volltextzugriff (PDF)

DNA methylation-independent reversion of gemcitabine resistance by hydralazine in cervical cancer cells

PloS one, 2012-03, Vol.7 (3), p.e29181

2012

Volltextzugriff (PDF)

Reactivation of Tumor Suppressor Genes by the Cardiovascular Drugs Hydralazine and Procainamide and Their Potential Use in Cancer Therapy

Clinical cancer research, 2003-05, Vol.9 (5), p.1596

2003

Volltextzugriff (PDF)

A combination of inhibitors of glycolysis, glutaminolysis and de novo fatty acid synthesis decrease the expression of chemokines in human colon cancer cells

Oncology letters, 2019-12, Vol.18 (6), p.6909-6916

2019

Volltextzugriff (PDF)

Antitumor Effects of Systemic DNAse I and Proteases in an In Vivo Model

Integrative cancer therapies, 2016-12, Vol.15 (4), p.NP35-NP43

2016

Volltextzugriff (PDF)

Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial

Annals of hematology, 2011-04, Vol.90 (4), p.379-387

2011

Volltextzugriff (PDF)

[Corrigendum] A combination of inhibitors of glycolysis, glutaminolysis and de novo fatty acid synthesis decrease the expression of chemokines in human colon cancer cells

Oncology letters, 2020-03, Vol.19 (3), p.2071-2071

2020

Volltextzugriff (PDF)

Feasibility and antitumor efficacy in vivo , of simultaneously targeting glycolysis, glutaminolysis and fatty acid synthesis using lonidamine, 6-diazo-5-oxo-L-norleucine and orlistat in colon cancer

Oncology letters, 2017-03, Vol.13 (3), p.1905-1910

2017

Volltextzugriff (PDF)

Impact of fixation artifacts and threshold selection on high resolution melting analysis for KRAS mutation screening

Molecular and cellular probes, 2017-10, Vol.35, p.34-43

2017

Volltextzugriff (PDF)

Antimetastatic effect of epigenetic drugs, hydralazine and valproic acid, in Ras-transformed NIH 3T3 cells

OncoTargets and therapy, 2018-01, Vol.11, p.8823-8833

2018

Volltextzugriff (PDF)

DNA methyltransferases 3a and 3b are differentially expressed in the early stages of a rat liver carcinogenesis model

Oncology reports, 2014-11, Vol.32 (5), p.2093-2103

2014

Volltextzugriff (PDF)

Hydralazine target: from blood vessels to the epigenome

Journal of translational medicine, 2006-02, Vol.4 (1), p.10-10, Article 10

2006

Volltextzugriff (PDF)

1 – 25 von 61

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(54)
Mit Volltextzugriff
(57)

Publikationsform

Artikel
(61)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Cancer progression mediated by horizontal gene transfer in an in vivo model

Landscape of Germline Genetic Variants in AGT, MGMT, and TP53 in Mexican Adult Patients with Astrocytoma

Orlistat as a FASN inhibitor and multitargeted agent for cancer therapy

A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes

Ether à go-go potassium channels as human cervical cancer markers

Familial erythrocytosis 2 and von Hippel-Lindau disease in the same pediatric patient

NAT2 global landscape: Genetic diversity and acetylation statuses from a systematic review

NAT2 global landscape: Genetic diversity and acetylation statuses from a systematic review

Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines

Analysis of the CAG tract length in the Androgen Receptor gene in Mexican patients with nonsyndromic cryptorchidism

ctDNA Is Useful to Detect Mutations at Codon 641 of Exon 16 of EZH2, a Biomarker for Relapse in Patients with Diffuse Large B-Cell Lymphoma

Growth inhibition and transcriptional effects of ribavirin in lymphoma

A Cohort Study of the Prognostic Impact of Exon-16 EZH2 Mutations in a Mexican-Mestizo Population of Patients with Diffuse Large B-Cell Lymphoma

DNA methylation-independent reversion of gemcitabine resistance by hydralazine in cervical cancer cells

Reactivation of Tumor Suppressor Genes by the Cardiovascular Drugs Hydralazine and Procainamide and Their Potential Use in Cancer Therapy

A combination of inhibitors of glycolysis, glutaminolysis and de novo fatty acid synthesis decrease the expression of chemokines in human colon cancer cells

Antitumor Effects of Systemic DNAse I and Proteases in an In Vivo Model

Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial

[Corrigendum] A combination of inhibitors of glycolysis, glutaminolysis and de novo fatty acid synthesis decrease the expression of chemokines in human colon cancer cells

Feasibility and antitumor efficacy in vivo , of simultaneously targeting glycolysis, glutaminolysis and fatty acid synthesis using lonidamine, 6-diazo-5-oxo-L-norleucine and orlistat in colon cancer

A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer

Impact of fixation artifacts and threshold selection on high resolution melting analysis for KRAS mutation screening

Antimetastatic effect of epigenetic drugs, hydralazine and valproic acid, in Ras-transformed NIH 3T3 cells

DNA methyltransferases 3a and 3b are differentially expressed in the early stages of a rat liver carcinogenesis model

Hydralazine target: from blood vessels to the epigenome

Suchergebnisse filtern